DOCSLIB.ORG

NON-ONCOLOGY N = 1919 Distinct NDC N = 244 Distinct Generic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NON-ONCOLOGY N = 1919 Distinct NDC N = 244 Distinct Generic NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 ABACAVIR 00378410591 ABACAVIR 31722055760 ABACAVIR 51079020406 ABACAVIR 68084002121 ABACAVIR SULFATE 00173066100 ABACAVIR SULFATE 00173066101 ABACAVIR SULFATE 00173066400 ABACAVIR SULFATE 35356007506 ABACAVIR SULFATE 35356007560 ABACAVIR SULFATE 49702022118 ABACAVIR SULFATE 49702022144 ABACAVIR SULFATE 49702022248 ABACAVIR SULFATE 51079020401 ABACAVIR SULFATE 54569488300 ABACAVIR SULFATE 54569539000 ABACAVIR SULFATE 54569635100 ABACAVIR SULFATE 60505358306 ABACAVIR SULFATE 65862007360 ABACAVIR SULFATE 68084002111 ABACAVIR SULFATE/LAMIVUDINE 00173074200 ABACAVIR SULFATE/LAMIVUDINE 35356010906 ABACAVIR SULFATE/LAMIVUDINE 35356010930 ABACAVIR SULFATE/LAMIVUDINE 49702020613 ABACAVIR SULFATE/LAMIVUDINE 54569559400 ABACAVIR SULFATE/LAMIVUDINE 54868560000 ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE 68180028607 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 00173069100 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 35356011606 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 35356011660 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 49702021718 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 54569519100 ABATACEPT 00003218811 ABATACEPT 00003218831 ABATACEPT/MALTOSE 00003218710 ABOBOTULINUMTOXINA 15054050001 ABOBOTULINUMTOXINA 15054053006 ADALIMUMAB 00074379902 ADALIMUMAB 00074433902 ADALIMUMAB 00074433906 ADALIMUMAB 00074433907 ADALIMUMAB 00074937402 ADALIMUMAB 54868482200 ADEFOVIR DIPIVOXIL 42794000308 ADEFOVIR DIPIVOXIL 61958050101 AFLIBERCEPT 61755000502 AGALSIDASE BETA 58468004001 AGALSIDASE BETA 58468004101 NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 AHF,HUMAN/VWF,HUMAN 00053762005 AHF,HUMAN/VWF,HUMAN 00053762010 AHF,HUMAN/VWF,HUMAN 00053762020 ALEFACEPT 00469002103 ALEFACEPT 00469002104 ALGLUCERASE 58468106001 ALGLUCOSIDASE ALFA 58468015001 ALGLUCOSIDASE ALFA 58468016001 ALGLUCOSIDASE ALFA 58468016002 ALPHA-1-PROTEINASE INHIBITOR 00053720102 ALPHA-1-PROTEINASE INHIBITOR 00161060130 ALPHA-1-PROTEINASE INHIBITOR 00944280102 ALPHA-1-PROTEINASE INHIBITOR 00944280201 ALPHA-1-PROTEINASE INHIBITOR 00944280202 ALPHA-1-PROTEINASE INHIBITOR 00944281201 ALPHA-1-PROTEINASE INHIBITOR 00944282202 ALPHA-1-PROTEINASE INHIBITOR 00944288401 ALPHA-1-PROTEINASE INHIBITOR 13533060130 ALPHA-1-PROTEINASE INHIBITOR 13533060135 ALPHA-1-PROTEINASE INHIBITOR 13533070001 ALPHA-1-PROTEINASE INHIBITOR 13533070002 AMBRISENTAN 61958080101 AMBRISENTAN 61958080102 AMBRISENTAN 61958080103 AMBRISENTAN 61958080201 AMBRISENTAN 61958080202 AMBRISENTAN 61958080203 ANAKINRA 55513017701 ANAKINRA 55513017728 ANAKINRA 66658023401 ANAKINRA 66658023407 ANAKINRA 66658023428 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944292102 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944292202 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944292302 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944292402 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294110 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294210 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294310 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294410 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294510 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294610 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944294810 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296010 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296110 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296210 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296310 NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296410 ANTIHEMOPH.FVIII PLAS/ALB FREE 00944296510 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394001201 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394001301 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394001401 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394001501 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394001603 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394002203 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394002303 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394002403 ANTIHEMOPH.FVIII PLAS/ALB FREE 58394002503 ANTIHEMOPHILIC FACTOR, HUM REC 00026378220 ANTIHEMOPHILIC FACTOR, HUM REC 00026378225 ANTIHEMOPHILIC FACTOR, HUM REC 00026378330 ANTIHEMOPHILIC FACTOR, HUM REC 00026378335 ANTIHEMOPHILIC FACTOR, HUM REC 00026378550 ANTIHEMOPHILIC FACTOR, HUM REC 00026378555 ANTIHEMOPHILIC FACTOR, HUM REC 00026378660 ANTIHEMOPHILIC FACTOR, HUM REC 00026378665 ANTIHEMOPHILIC FACTOR, HUM REC 00026378770 ANTIHEMOPHILIC FACTOR, HUM REC 00026378775 ANTIHEMOPHILIC FACTOR, HUM REC 00026379220 ANTIHEMOPHILIC FACTOR, HUM REC 00026379330 ANTIHEMOPHILIC FACTOR, HUM REC 00026379550 ANTIHEMOPHILIC FACTOR, HUM REC 00026379660 ANTIHEMOPHILIC FACTOR, HUM REC 00026379770 ANTIHEMOPHILIC FACTOR, HUM REC 00053813001 ANTIHEMOPHILIC FACTOR, HUM REC 00053813002 ANTIHEMOPHILIC FACTOR, HUM REC 00053813004 ANTIHEMOPHILIC FACTOR, HUM REC 00053813005 ANTIHEMOPHILIC FACTOR, HUM REC 00053813102 ANTIHEMOPHILIC FACTOR, HUM REC 00053813202 ANTIHEMOPHILIC FACTOR, HUM REC 00053813302 ANTIHEMOPHILIC FACTOR, HUM REC 00053813402 ANTIHEMOPHILIC FACTOR, HUM REC 00053813502 ANTIHEMOPHILIC FACTOR, HUM REC 00944283110 ANTIHEMOPHILIC FACTOR, HUM REC 00944283210 ANTIHEMOPHILIC FACTOR, HUM REC 00944283310 ANTIHEMOPHILIC FACTOR, HUM REC 00944283401 ANTIHEMOPHILIC FACTOR, HUM REC 00944283410 ANTIHEMOPHILIC FACTOR, HUM REC 00944283501 ANTIHEMOPHILIC FACTOR, HUM REC 00944283510 ANTIHEMOPHILIC FACTOR, HUM REC 00944284110 ANTIHEMOPHILIC FACTOR, HUM REC 00944284210 ANTIHEMOPHILIC FACTOR, HUM REC 00944284310 ANTIHEMOPHILIC FACTOR, HUM REC 00944284410 ANTIHEMOPHILIC FACTOR, HUM REC 00944284510 NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 ANTIHEMOPHILIC FACTOR, HUM REC 58394000602 ANTIHEMOPHILIC FACTOR, HUM REC 58394000604 ANTIHEMOPHILIC FACTOR, HUMAN 00053763302 ANTIHEMOPHILIC FACTOR, HUMAN 00053763402 ANTIHEMOPHILIC FACTOR, HUMAN 00053765601 ANTIHEMOPHILIC FACTOR, HUMAN 00053765602 ANTIHEMOPHILIC FACTOR, HUMAN 00053765604 ANTIHEMOPHILIC FACTOR, HUMAN 00053765605 ANTIHEMOPHILIC FACTOR, HUMAN 00944293001 ANTIHEMOPHILIC FACTOR, HUMAN 00944293101 ANTIHEMOPHILIC FACTOR, HUMAN 00944293201 ANTIHEMOPHILIC FACTOR, HUMAN 00944293301 ANTIHEMOPHILIC FACTOR, HUMAN 00944293502 ANTIHEMOPHILIC FACTOR, HUMAN 00944293504 ANTIHEMOPHILIC FACTOR, HUMAN 00944394002 ANTIHEMOPHILIC FACTOR, HUMAN 00944394202 ANTIHEMOPHILIC FACTOR, HUMAN 00944394402 ANTIHEMOPHILIC FACTOR, HUMAN 00944394602 ANTIHEMOPHILIC FACTOR, HUMAN 13533066520 ANTIHEMOPHILIC FACTOR, HUMAN 13533066530 ANTIHEMOPHILIC FACTOR, HUMAN 13533066550 ANTIHEMOPHILIC FACTOR, HUMAN 76125025020 ANTIHEMOPHILIC FACTOR, HUMAN 76125050030 ANTIHEMOPHILIC FACTOR, HUMAN 76125066730 ANTIHEMOPHILIC FACTOR, HUMAN 76125066750 ANTIHEMOPHILIC FACTOR,HUMAN 00053760501 ANTIHEMOPHILIC FACTOR/VWF 00053761505 ANTIHEMOPHILIC FACTOR/VWF 00053761510 ANTIHEMOPHILIC FACTOR/VWF 00053761520 ANTIHEMOPHILIC FACTOR/VWF 63833061502 ANTIHEMOPHILIC FACTOR/VWF 63833061602 ANTIHEMOPHILIC FACTOR/VWF 63833061702 ANTIHEMOPHILIC FACTOR/VWF 67467018101 ANTIHEMOPHILIC FACTOR/VWF 67467018102 ANTIHEMOPHILIC FACTOR/VWF 67467018201 ANTIHEMOPHILIC FACTOR/VWF 67467018202 ANTIHEMOPHILIC FACTOR/VWF 68516460101 ANTIHEMOPHILIC FACTOR/VWF 68516460201 ANTIHEMOPHILIC FACTOR/VWF 68516460302 ANTIHEMOPHILIC FACTOR/VWF 68516460402 ANTI-INHIBITOR COAGULANT COMP. 64193022203 ANTI-INHIBITOR COAGULANT COMP. 64193022204 ANTI-INHIBITOR COAGULANT COMP. 64193022205 ANTI-INHIBITOR COAGULANT COMP. 64193022302 ANTI-INHIBITOR COAGULANT COMP. 64193022402 ANTI-INHIBITOR COAGULANT COMP. 64193022502 ANTI-INHIBITOR COAGULANT COMP. 64193042302 NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 ANTI-INHIBITOR COAGULANT COMP. 64193042402 ANTI-INHIBITOR COAGULANT COMP. 64193042502 APOMORPHINE HCL 15054021101 APOMORPHINE HCL 15054021105 APOMORPHINE HCL 27505000401 APOMORPHINE HCL 27505000405 ATAZANAVIR SULFATE 00003362212 ATAZANAVIR SULFATE 00003362312 ATAZANAVIR SULFATE 00003362412 ATAZANAVIR SULFATE 00003363112 ATAZANAVIR SULFATE 35356006806 ATAZANAVIR SULFATE 35356006860 ATAZANAVIR SULFATE 35356011406 ATAZANAVIR SULFATE 35356011430 ATAZANAVIR SULFATE 35356020760 ATAZANAVIR SULFATE 54569553000 ATAZANAVIR SULFATE 54569553200 ATAZANAVIR SULFATE 54569586400 ATAZANAVIR SULFATE 54868485400 ATAZANAVIR SULFATE 54868485700 ATAZANAVIR SULFATE 54868583800 AZATHIOPRINE 00054408425 AZATHIOPRINE 00054808425 AZATHIOPRINE 00378100501 AZATHIOPRINE 21695048475 AZATHIOPRINE 23490511009 AZATHIOPRINE 38779031203 AZATHIOPRINE 38779031204 AZATHIOPRINE 38779031206 AZATHIOPRINE 43353068660 AZATHIOPRINE 43353074560 AZATHIOPRINE 49452078302 AZATHIOPRINE 51079062001 AZATHIOPRINE 51079062006 AZATHIOPRINE 51552077902 AZATHIOPRINE 51552077904 AZATHIOPRINE 51552077905 AZATHIOPRINE 51927225800 AZATHIOPRINE 52372072801 AZATHIOPRINE 52372072802 AZATHIOPRINE 52372072803 AZATHIOPRINE 52372072804 AZATHIOPRINE 52959007900 AZATHIOPRINE 54868092101 AZATHIOPRINE 54868092102 AZATHIOPRINE 54868092104 AZATHIOPRINE 54868531000 NON-ONCOLOGY n = 1919 distinct NDC n = 244 distinct Generic Names GENERIC NAME NDC 11 AZATHIOPRINE 54868531001 AZATHIOPRINE 54868531002 AZATHIOPRINE 54868531003 AZATHIOPRINE 54868531004 AZATHIOPRINE 62991218901 AZATHIOPRINE 62991218903 AZATHIOPRINE 62991218904 AZATHIOPRINE 65483059010 AZATHIOPRINE 65649023141 AZATHIOPRINE 65649024141 AZATHIOPRINE 68084022901 AZATHIOPRINE 68084022911 AZATHIOPRINE 68382000301 AZATHIOPRINE 68382000305 AZATHIOPRINE 68462050201 AZATHIOPRINE SODIUM 55390060020 AZTREONAM LYSINE 61958090101 BASILIXIMAB 00078033184 BASILIXIMAB 00078039361 BCG VACCINE 00052060302 BELATACEPT 00003037113 BELIMUMAB 49401010101 BELIMUMAB 49401010201 BETAINE 66621400001 BOCEPREVIR 00085031402 BOSENTAN 66215010103 BOSENTAN 66215010106 BOSENTAN 66215010203 BOSENTAN 66215010206 C1 ESTERASE INHIBITOR 42227008105 C1 ESTERASE INHIBITOR 63833082502
Load more

Recommended publications
  • Specialty Drug List 10-22-12 Final
    Iowa Medicaid Specialty Drug List Effective 10/22/2012 “Specialty” drugs include biological drugs, blood-derived products, complex molecules, and select oral, injectable, and infused medications identified by the Department and reimbursed at AWP-17% plus the dispensing fee. Specialty pricing will be applied to both the brand and generic drug products. NOTE: See the PDL at www.iowamedicaidpdl.com for specific PA criteria for the following drugs. BRAND NAME GENERIC NAME AGENTS FOR GAUCHER DISEASE ELELYSO taliglucerase alfa VPRIV velaglucerase alfa ALS RILUTEK riluzole ALCOHOL DEPENDENCE VIVITROL naltrexone AMINOGLYCOSIDES TOBI tobramycin ANTI-ASTHMATICS ALPHA PROTEINASE INHIBITORS ARALAST proteinase inhibitor ARALAST NP proteinase inhibitor PROLASTIN, C proteinase inhibitor ZEMAIRA alpha-1 proteinase inhibitor ANTIASTHMATIC - BETA - ADRENERGICS BRETHINE INJECTION turbutaline sulfate ANTIASTHMATIC - HYDRO-LYTIC ENZYMES KALYDECO ivacaftor ANTIBIOTICS - MISC. CAYSTON aztreonam lysine for inhal soln ANTI-CATAPLECTIC AGENTS XYREM sodium oxybate oral solution ANTICOAGULANTS ARIXTRA fondaparinux sodium FRAGMIN dalteparin sodium INNOHEP tinzaparin sodium LOVENOX enoxaparin sodium ANTICONVULSANTS SABRIL vigabatrin ANTIDOTES FERRIPROX deferiprone ANTIDOTES - CHELATING AGENTS CHEMET succimer EXJADE deferasirox tab for oral susp Page 1 of 10 ANTIEMETIC - TETRAHYDROCANNABINOL (THC) DERIVATIVES MARINOL dronabinol ANTIFUNGALS - ASSORTED AMBISOME amphotericin B Liposome IV for suspension ANCOBON flucytosine CANCIDAS caspofungin acetate for IV solution
    [Show full text]
  • Specialty Drug Benefit Document
    Louisiana Healthcare Connections Specialty Drug Benefit ouisiana Healthcare Connections provides coverage of a number of specialty drugs. All specialty drugs, such as biopharmaceuticals and injectables, require a prior authorization (PA) to be approved for L payment by Louisiana Healthcare Connections. PA requirements are programmed specific to the drug. Since the list of specialty drugs changes over time due to new drug arrivals and other market conditions, it is important to contact Provider Services at 1-866-595-8133 or check the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com for updates to this benefit. Requests for specialty drugs can be submitted to Louisiana Healthcare Connections by filling out the Medication Prior Authorization Form that is available on the Louisiana Healthcare Connections website at www.LouisianaHealthConnect.com and faxing the request as instructed on the form. Louisiana Healthcare Connections members can receive the specialty drugs they require at any outpatient pharmacy enrolled in our pharmacy network that can supply specialty drugs. Providers that wish to have drugs distributed by a SPECIALTY PHARMACY should FAX the request to 1-866-399-0929 for review. If a provider wishes to dispense a specialty drug from OFFICE STOCK, the provider should FAX the request to Louisiana Healthcare Connections at 1-877-401-8172 for review. BRAND NAME INGREDIENTS SPECIAL INSTRUCTIONS ACTEMRA TOCILIZUMAB ACTHAR HP CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA-1B ADAGEN PEGADEMASE BOVINE Limited Distribution
    [Show full text]
  • MSM Chapter 1200 3/1/21
    MEDICAID SERVICES MANUAL TRANSMITTAL LETTER February 23, 2021 TO: CUSTODIANS OF MEDICAID SERVICES MANUAL FROM: JESSICA KEMMERER, HIPAA PRIVACY AND CIVIL RIGHTS OFFICER /Jessica Kemmerer/ BACKGROUND AND EXPLANATION The DHCFP is proposing revisions to Medicaid Services Manual (MSM), Chapter 1200 – Prescribed Drugs, Appendix A, to reflect recommendations approved on October 22, 2020, by the Drug Use Review (DUR) Board. The proposed changes include the addition of new prior authorization criteria for Doxepine Topical, the addition of new prior authorization criteria for Zeposia® (ozanimod), addition of new prior authorization for Evenity® (romosozumab-aqqg), Prolia® (denosumab), Forteo® (teriparatide) and Tymlos® (abaloparatide) within a new combined osteoporosis agents section, and addition of new prior authorization criteria for Orilissa® (elagolix) and Oriahnn® (elagolix, estradiol, and norethindrone) within a new Gonadorpin Hormone Receptor (GnRH) Antagonist and Combinations section. Additionally, the DHCFP is proposing revisions to the existing prior authorization criteria for psychotropic medications for children and adolescents, and revision to the existing clinical criteria for Epidiolex® (cannabidiol). Throughout the chapter, grammar, punctuation and capitalization changes were made, duplications removed, acronyms used and standardized, and language reworded for clarity. Renumbering and re- arranging of sections was necessary. These changes are effective March 1, 2021. MATERIAL TRANSMITTED MATERIAL SUPERSEDED MTL N/A MTL N/A MSM Ch 1200 – Prescribed Drugs MSM Ch 1200 – Prescribed Drugs Background and Explanation of Policy Changes, Manual Section Section Title Clarifications and Updates Appendix A Psychotropic Added new policy language criteria on which specific Section N Medications for drug classes may bypass polypharmacy clinical criteria. Children and Adolescents Appendix A Reserved for Future Created a new section titled “Doxepin Topical.” Added Section W Use new prior authorization criteria for doxepin topical.
    [Show full text]
  • OMONTYS® Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- These highlights do not include all the information needed to use Dosage Form Strengths OMONTYS® safely and effectively. See full prescribing information for OMONTYS. Single use vials 2 mg/0.5 mL, 3 mg/0.5 mL, (preservative-free) 4 mg/0.5 mL, 5 mg/0.5 mL, and OMONTYS® (peginesatide) Injection, 6 mg/0.5 mL for intravenous or subcutaneous use Single use pre-filled syringes 1 mg/0.5 mL, 2 mg/0.5 mL, Initial U.S. Approval: 2012 (preservative-free) 3 mg/0.5 mL, 4 mg/0.5 mL, 5 mg/0.5 mL, and 6 mg/0.5 mL WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL Multiple use vials 10 mg/mL and 20 mg/2 mL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, (with preservative) THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE -------------------------------CONTRAINDICATIONS------------------------------ See full prescribing information for complete boxed warning. Uncontrolled hypertension (4). Chronic Kidney Disease: In controlled trials, patients experienced greater risks for -----------------------WARNINGS AND PRECAUTIONS------------------------ death, serious adverse cardiovascular reactions, and stroke Increased Mortality, Myocardial Infarction, Stroke, and when administered erythropoiesis-stimulating agents (ESAs) Thromboembolism: Using ESAs to target a hemoglobin level of to target a hemoglobin level of greater than 11 g/dL (5.1). greater than 11 g/dL increases the risk of serious adverse No trial has identified a hemoglobin target level, ESA dose, or cardiovascular reactions and has not been shown to provide dosing strategy that does not increase these risks (5.1). additional benefits (5.1).
    [Show full text]
  • Overview of Antibody Drug Delivery
    pharmaceutics Review Overview of Antibody Drug Delivery Sahar Awwad 1,2,* ID and Ukrit Angkawinitwong 1 1 UCL School of Pharmacy, London WC1N 1AX, UK; [email protected] 2 National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1 V9EL, UK * Correspondence: [email protected]; Tel.: +44-207-753-5802 Received: 27 March 2018; Accepted: 29 June 2018; Published: 4 July 2018 Abstract: Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins, which are used to treat a wide number of diseases (e.g., oncology, inflammation and autoimmune diseases). Monoclonal antibody technologies are continuing to evolve to develop medicines with increasingly improved safety profiles, with the identification of new drug targets being one key barrier for new antibody development. There are many opportunities for developing antibody formulations for better patient compliance, cost savings and lifecycle management, e.g., subcutaneous formulations. However, mAb-based medicines also have limitations that impact their clinical use; the most prominent challenges are their short pharmacokinetic properties and stability issues during manufacturing, transport and storage that can lead to aggregation and protein denaturation. The development of long acting protein formulations must maintain protein stability and be able to deliver a large enough dose over a prolonged period. Many strategies are being pursued to improve the formulation and dosage forms of antibodies to improve efficacy and to increase the range of applications for the clinical use of mAbs. Keywords: antibodies; protein; pharmacokinetics; drug delivery; stability 1.
    [Show full text]
  • Peginesatide for Anaemia in Chronic Kidney Disease – First and Second Line
    Peginesatide for anaemia in chronic kidney disease – first and second line June 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The NIHR Horizon Scanning Centre Research Programme is part of the National Institute for Health Research www.nhsc-healthhorizons.org.uk June 2012 Peginesatide for anaemia in chronic kidney disease – first and second line Target group • Symptomatic anaemia: patients on dialysis with chronic kidney disease (CKD) – first and second line. Background Human erythropoietin (EPO) is a protein produced by the kidneys that stimulates the production of red blood cells. Because the kidney is the sole source of EPO synthesis in adults, the reduction in kidney mass that occurs in progressive CKD often causes impairment of EPO production, resulting in anaemia. Technology description Peginesatide (AF-37702) is a synthetic peptide mimetic of EPO that binds directly to the erythropoietin receptor on red blood cell precursors to stimulate red cell formation. Peginesatide is intended as a substitute for currently available erythropoiesis stimulating agents (ESAs) in the treatment of anaemia in CKD dialysis patients. It is administered intravenously (IV) or subcutaneously (SC) at 0.04 mg/kg once monthly. After the initial dose, doses may be titrated to achieve a haemoglobin (Hb) level in the range of 10 to 12g/dL. Peginesatide is also in phase II clinical trials for pure red cell aplasia.
    [Show full text]
  • Pipelinetr Ends
    June 2011 PIPELINE TRxENDS PIPELINE TR ENDS is produced by the x 1-3 Promising New Agents 5 Industry Trends University of Massachusetts Medical School’s 4 Projected Generic Entry 5 Additional Promising Clinical Pharmacy Services division and 4 Investigational Indications New Agents distributed to our clients twice yearly. 4 FDA Updates In This Issue Promising New Promising New Agents Agents Aflibercept Drug Name: Aclidinium bromide Drug Name: Aflibercept BLA submitted Manufacturer: Almirall, Forest Manufacturer: Regeneron, Bayer for wet age- Phase III Indication: COPD BLA Indication: Wet AMD related macular Formulation: Dry powder inhaler Formulation: Intravitreal injection degeneration Dimethyl fumarate Aclidinium bromide, a long-acting, inhaled Aflibercept is under FDA review for the treatment NDA submission anticholinergic bronchodilator, is an antagonist at of the neovascular form of age-related macular planned for the M2 and M3 muscarinic receptors. It is being degeneration (wet AMD). By inhibiting vascular relapsing-remitting multiple sclerosis studied for the treatment of chronic obstructive endothelial and placental growth factors, aflibercept pulmonary disease (COPD). may reduce the abnormal growth of blood vessels Projected Three Phase III, randomized, double-blind trials that damage the retina through blood and fluid leaks. Generic Entry compared aclidinium bromide 200 μg and 400 μg In two double-blind, non-inferiority, Phase III ® Nasacort AQ twice daily to placebo in patients with moderate to studies, VIEW 1 (N=1,217) and VIEW 2 (N=1,240), Levaquin® severe COPD. In each study, the primary endpoint patients with wet AMD were randomized to Uroxatral® Anzemet® was the change in morning trough forced expiratory intravitreal aflibercept 0.5 mg monthly, 2 mg monthly, Zyprexa® volume in one second (FEV1), from baseline to week or 2 mg every two months following three monthly Zyprexa® Zydis® 12.
    [Show full text]
  • Management of Anemia on Hemodialysis
    Chapter 17 Management of Anemia on Hemodialysis Konstantinos Pantelias and Eirini Grapsa Additional information is available at the end of the chapter http://dx.doi.org/10.5772/ 52399 1. Introduction The definition of anemia is controversial. The WHO defines anemia as hemoglobin (Hb)<13 g/dL for men and <12 g/dL for women [1]. The National Kidney Foundation's Kidney Dis‐ ease Outcomes Quality Initiative, which is the criteria used for Medicare reimbursement, de‐ fines anemia in adult men and postmenopausal women as Hb<12 g/dL, or <11 g/dL in a premenopausal woman [2]. Anemia represents a significant problem to deal with in patients with chronic kidney disease (CKD) on hemodialysis (HD). Renal anemia is typically an iso‐ lated normochromic, normocytic anemia with no leukopenia or thrombocytopenia [3]. This is a frequent complication and contributes considerably to reduced quality of life (QoL) [4-6] of patients with CKD. It has also been associated with a number of adverse clinical out‐ comes, increased morbidity and mortality [5, 7-13]. In general, there is a progressive increase in the incidence and severity of anemia with declining renal function. The reported preva‐ lence of anemia by CKD stage varies significantly and depends, to a large extent, on the def‐ inition of anemia and whether study participants selected from the general population, are at a high risk for CKD. Data from the National Health and Nutrition Examination Survey (NHANES) showed that the distribution of Hb levels starts to fall at an estimated glomeru‐ lar filtration rate (eGFR) of less than 75 ml/min per 1.73 m2 in men and 45 ml/min per 1.73 m2 in women [14].
    [Show full text]
  • WHO Drug Information Vol
    WHO Drug Information Vol. 26, No. 4, 2012 WHO Drug Information Contents International Regulatory Regulatory Action and News Harmonization New task force for antibacterial International Conference of Drug drug development 383 Regulatory Authorities 339 NIBSC: new MHRA centre 383 Quality of medicines in a globalized New Pakistan drug regulatory world: focus on active pharma- authority 384 ceutical ingredients. Pre-ICDRA EU clinical trial regulation: public meeting 352 consultation 384 Pegloticase approved for chronic tophaceous gout 385 WHO Programme on Tofacitinib: approved for rheumatoid International Drug Monitoring arthritis 385 Global challenges in medicines Rivaroxaban: extended indication safety 362 approved for blood clotting 385 Omacetaxine mepesuccinate: Safety and Efficacy Issues approved for chronic myelo- Dalfampridine: risk of seizure 371 genous leukaemia 386 Sildenafil: not for pulmonary hyper- Perampanel: approved for partial tension in children 371 onset seizures 386 Interaction: proton pump inhibitors Regorafenib: approved for colorectal and methotrexate 371 cancer 386 Fingolimod: cardiovascular Teriflunomide: approved for multiple monitoring 372 sclerosis 387 Pramipexole: risk of heart failure 372 Ocriplasmin: approved for vitreo- Lyme disease test kits: limitations 373 macular adhesion 387 Anti-androgens: hepatotoxicity 374 Florbetapir 18F: approved for Agomelatine: hepatotoxicity and neuritic plaque density imaging 387 liver failure 375 Insulin degludec: approved for Hypotonic saline in children: fatal diabetes mellitus
    [Show full text]
  • Therapeutic Class Overview Erythropoiesis-Stimulating Agents
    Therapeutic Class Overview Erythropoiesis-Stimulating Agents Therapeutic Class · Overview/Summary: The erythropoiesis-stimulating agents (ESAs) currently available are darbepoetin alfa (Aranesp®), epoetin alfa (Epogen®, Procrit®) and peginesatide (Omontys®).1-4 There is no generic ESA is currently available in the United States. All ESAs are approved by the Food and Drug Administration (FDA) for the treatment of anemia in patients with chronic kidney disease; however, peginesatide is only approved for use in patients on dialysis. Darbepoetin alfa and epoetin alfa are also indicated for the treatment of anemia in cancer patients receiving chemotherapy. Moreover, epoetin alfa products are also FDA-approved for the treatment of anemia due to zidovudine therapy in patients with human immunodeficiency virus infection as well as to reduce the need for allogeneic blood transfusion in anemic patients who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery.1-5 Both epoetin alfa and darbepoetin alfa are manufactured via recombinant deoxyribonucleic acid technology and have similar biological effects as endogenous erythropoietin.6 Although darbepoetin alfa has identical pharmacological actions, the additional carbohydrate chains prolong its elimination half-life by two- to three-fold compared to epoetin alfa. Because of this, darbepoetin alfa is dosed less frequently compared to epoetin alfa. Peginesatide is structurally distinct from epoetin alfa and darbepoetin alfa in that it is a synthetic dimeric peptide
    [Show full text]
  • Detection and Method Validation of Peginesatide in Human Serum by Means of LC-MS/MS
    Lecture MANFRED DONIKE WORKSHOP Ines Möller, Andreas Thomas, Hans Geyer, Wilhelm Schänzer, Mario Thevis Detection and method validation of peginesatide in human serum by means of LC-MS/MS Institute of Biochemistry, German Sport University Cologne, Cologne, Germany Abstract Erythropoiesis-stimulating agents (ESAs) have frequently been confessed to be illicitly used in elite sports due to their endurance enhancing effects. Recently, peginesatide, the first representative of a new generation of ESAs, referred to as Erythropoietin (EPO)-mimetic peptides, obtained approval in the USA under the trade name Omontys® for the treatment of anemic patients on dialysis. Lacking sequence homology with EPO, it consists of a pegylated homodimeric peptide of approximately 45 kDa, and thus, specific approaches for the determination of peginesatide in blood had to be developed as conventional detection assays for EPO would not succeed in detecting the EPO-mimetic peptides. Therefore, a mass spectrometric detection method in human serum was developed targeting a proteotypic pentapeptide fragment after protein precipitation, subtilisin digestion, and cation-exchange purification. Eventually, the method was validated for qualitative purposes and proved to be specific, sensitive (limit of detection 1 ng/mL), and both precise and linear over a wide range of expected blood concentrations. Thus, the assay not only demonstrated its fitness for purpose for an application in routine doping control analysis but also allows for a detection of therapeutic doses of peginesatide in human serum for approximately one week when considering plasma maximum concentrations of about 1,000 ng/mL after a single intravenous administration of 0.05 mg/kg bodyweight to healthy volunteers and an observed half-live of around one day.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]